Poll

Poll: Is DRE still a relevant tool in the management of prostate cancer?

Do you feel that DRE is still a relevant tool in the management of prostate cancer? Take our latest poll and let us know.

Yes
No
Not sure

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Ruben Olivares, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
Urology in focus: Key moments from 2025
July 18th 2025

Urology in focus: Key moments from 2025

Hannah Clarke
Take a look back through some of the top stories from the first half of the year.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Carotuximab plus apalutamide demonstrates safety, tolerability in mCRPC
July 15th 2025

Carotuximab plus apalutamide demonstrates safety, tolerability in mCRPC

Hannah Clarke
The company said it plans to report interim efficacy data from the trial in September 2025.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Patient talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
July 10th 2025

FDA grants breakthrough device designation for ArteraAI Prostate tool

Benjamin P. Saylor Hannah Clarke
“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
July 10th 2025

EMBARK: Significant OS gains seen with enzalutamide plus leuprolide in nmHSPC

Benjamin P. Saylor
According to the news release, detailed OS data from EMBARK are set to be presented at an upcoming medical conference.
© 2025 MJH Life Sciences

All rights reserved.